Conduit Pharmaceuticals Inc (CDT) 銘柄情報

BOTTOM $3.30

News on 27th!

INTERESTING!

Carefully read through the SEC filing: stock was valued by a stock evaluation expert for purpose of financing, and he put its value at $14.40 MINIMUM (post split adjusted). There’s a reason to hold!

TEN:


1.) Conduit Pharmaceuticals Announces Leadership Changes—founder returns.

2.) Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects.

3.) Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program.

4.) Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways.

5.) Conduit Pharmaceuticals Receives U.S., Korean, Japanese and Austrailian Patent Approval For Its Lead Asset Targeting Autoimmune Diseases.

6.) Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model.

7.) Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline.

8.) RS restructure complete.

9.) Insider buying!

10.) TWO pharma attorneys buy 2.5% of company in past 20 days.

EXPECT BIG NEWS…

CDT! New 52+week low

R/S effective 05/19

🆙 Bottom found, now UP!

Korean patent today!

ANOTHER NEW PATENT!

As I stated, shares are being accumulated during the r/s fear period. I’d hate to be the fool that sold and in two weeks is kicking themselves.

CDT, new 52 week low

TOP REASONS buy CDT today!

1.) Conduit Pharmaceuticals Announces Leadership Changes—founder returns.

2.) Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects.

3.) Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program.

4.) Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways.

5.) Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases.

6.) Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model.

7.) Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline.

CDT LAWYER BUYS 1% OF OUTSTANDING COMMON SHARES before stepping down from Board!

GOING PRIVATE?

A newly appointed CEO, who is also the founder, is ready to capitalize on the opportunity to transition CDT into a private entity.

The approach to increase corporate value may involve:

1. Streamlining the investor base by reducing the number of board members and executives.
2. Utilizing news of a reverse stock split to purchase shares at a lower cost, which could temporarily lower the stock price.
3. Following the reverse stock split, significantly decreasing the current 4,700 shareholders through the recently announced $1 million share repurchase initiative.
4. Allocating additional shares to SARBORG AI, where the new CEO holds a board position.
5. Initiating licensing agreements for AZD 1656.
6. Introducing new research drugs into the development pipeline.
7. Improving collaboration with Charles River Lab.

The objective is to shift from a public to a private company and ultimately achieve the highest possible sale value.

DON’T MISS TODAY’S SALE!

✅✅✅

Charles River news will be HUGE!

1️⃣2️⃣3️⃣ STRATEGY:

“ Conduit's filing of novel cocrystal patents for tapinarof represents a significant strategic move in pharmaceutical lifecycle management. With VTAMA® facing patent expiration in 2027, this timing is particularly shrewd. The dual active cocrystal approach isn't merely a reformulation but creates a new composition of matter by pairing tapinarof with complementary agents addressing both disease pathology and symptom management.

This strategy creates three distinct value drivers: potential clinical superiority by targeting symptoms like pain and itch that current formulations neglect, extended market exclusivity beyond the 2027 cliff, and expanded therapeutic applications into the broader $233.6 billion inflammatory disease market.

The intellectual property strategy is particularly noteworthy as it comes at a crucial inflection point when tapinarof is expanding beyond dermatology into cutaneous lupus and other autoimmune indications. By filing now, Conduit establishes IP protection covering these emerging applications just as clinical evidence is being generated.

The reference to Organon's $1.2 billion acquisition of VTAMA® demonstrates the established commercial value of the underlying asset. This new patent approach positions Conduit to capture significant licensing value by offering potential partners extended commercial runway as they explore tapinarof's broader therapeutic potential across the rapidly growing anti-inflammatory market.”

POPPING!

BULL 🐂🏋🏼‍♀️

ANOTHER patent today!

Absolutely Johhnydollar 🪜 💹 😇

The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value.

“Given the current market value of our common stock we believe it is prudent to have the option to re-purchase our shares using our existing cash reserves,” said Dr. David Tapolczay, Chief Executive Officer of Conduit. “With multiple milestones anticipated across our pipeline this year.”

$CDT

A ladder to heaven ✨️ 😍 🙌.

Looking good 💹 😃 After market party 🥳 🍸️

$CDT

MASSIVE VOLUME=ROCK SOLID COMPANY

Expect that end of day JUMP!

Nice 💹

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

April 10, 2025

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value.

Under the program, Conduit may repurchase shares from time to time through open market transactions or other methods in compliance with SEC Rule 10b-18. Purchases will be executed by The Benchmark Company, the Company's appointed broker, and will be subject to market conditions, corporate liquidity requirements, regulatory considerations, and other factors.

The share repurchase program does not obligate the Company to acquire a particular amount of common stock and the Company will use its discretion to repurchase shares. The program has no fixed expiration date and may be adjusted or terminated at any time by the Company.

“Given the current market value of our common stock we believe it is prudent to have the option to re-purchase our shares using our existing cash reserves,” said Dr. David Tapolczay, Chief Executive Officer of Conduit. “With multiple milestones anticipated across our pipeline this year, including preclinical data readouts and Phase II trial initiation for AZD1656, we believe in a balanced approach to capital allocation.”

About Conduit Pharmaceuticals

Conduit is a multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

https://ih.advfn.com/stock-market/NASDAQ/conduit-pharmaceuticals-CDT/stock-news/95822833/conduit-pharmaceuticals-announces-up-to-1-000-000

$CDT

INSTITUTIONAL BUYING

CDT...........................................https://stockcharts.com/h-sc/ui?s=CDT&p=W&b=5&g=0&id=p86431144783

CORPORATE CONFIDENCE!

MILLION share buyback WOW

$ 🚀 $

SHARE BUY BACK!

CDT extends SARBORG contract for AI pharmaceutical research—results will rocket 🚀 sp.

Look at the runs this stock makes. ↗️

8 Million in NEW funding.

PATENT for AZD1656 secured NOW in : USA, Japan, Australia.

Coming off bottom—MASSIVE upside with razor thin float.

NICE! Capital infusion…

8 K/A filed 2 April 2025

“ Item 8.01. Other Events

Nasdaq Deficiency Compliance Update

On March 7, 2025, the Company applied to the Nasdaq Capital Market and is currently compliant with the Market Value of Publicly Held Securities continued listing standard of Nasdaq Capital Market being greater than $1.0 million. On March 31, 2025, the Company submitted to Nasdaq on a pro-forma basis, as of March 31, 2025, a financial statement demonstrating its compliance with the Nasdaq Capital Market Equity Standard of Stockholder’s Equity greater than $2.5 million, after anticipating all first quarter 2025 expected losses, reflecting Stockholder’s Equity of $2.8 million, which has significantly increased since the Company’s fiscal year end as a result of (i) fundraising of an additional $8.332 million from the Company’s ongoing at the market offering, (ii) conversion of $1.785 million into 924,200 shares of common stock from previously existing debt, and (iii) capitalization of certain invoices and fees. The Company was compliant with the Nasdaq Capital Market Equity Standard of Stockholder’s Equity greater than $2.5 million as of March 31, 2025, and continues to remain compliant as of the date of the filing of this Amendment.”

CDT......................................................p/m

CDT....................................................https://stockcharts.com/h-sc/ui?s=CDT&p=W&b=5&g=0&id=p86431144783

CDT, new 52 week low

$1.10 keep an eye hold a few ..low floater don't want to lose $1 status 

CDT under $2

Offering should be soon now as $1 requirement met so they can dilute now to get the $2.5 million Nasdaq
Requirement next..
10:41 AM EST, 03/06/2025 (MT Newswires) -- Conduit Pharmaceuticals (CDT) said Thursday that a Nasdaq hearing panel granted it an extension to meet listing requirements, with plans to transfer its shares to the Nasdaq Capital Market.The company said it must submit an application for the transfer by March 12 and meet all Nasdaq listing standards by March 31.Conduit said it had been at risk of delisting for not meeting requirements related to minimum bid price, market value of publicly held shares, and market value of listed securities. It regained compliance with the minimum bid price rule as of Feb. 26, according to the company.Following the transfer, the company expects to meet the continued listing requirement for publicly held shares above $1.0 million and believes it will satisfy the Nasdaq equity standard of stockholder's equity above $2.5 million before the March 31 deadline, though it cautioned that compliance is not assured.

Hi do you know if they closed it ? Thankyou not financial advice

CDT, new 52/week low

$CDT offering anytime now . s1 is effective.
Be careful 

CDT: THANKS, nice!!!!

News out low float 600k $2.13 + 20% partners Charles Rivers

CDT: I'm out --- thank you for a NICE profit, CDT Company!! And may it SOAR up more to $5.00 for everybody else before the Close today!! GOD BLESS!!! Am I a nice, gregarious, & otherwise GRACIOUS fellow, or WHAT, Dudes??!!!

And now, I'm right back to my new, "HOT-BLONDE-CHICKS-TUB", by Peleton!! (That's ME, below, live right now!!!)